CTLA4 and melanoma: Besides the small molecule inhibitor PLX4032, which is specific for melanomas and presumably other cancers with V600E mutated BRAF [2], and CTLA-4 blocking antibodies [1], there are no promising single compound therapies in the pipeline, and, unfortunately, some melanomas develop drug resistance by MAPK reactivation [3].